tradingkey.logo
tradingkey.logo
Search

GSK says Depemokimab Accepted For Review By Health Canada For Treatment Of Asthma With Type 2 Inflammation

ReutersMay 26, 2025 1:23 PM
facebooktwitterlinkedin

- GSK plc GSK.L:

  • GSK: DEPEMOKIMAB ACCEPTED FOR REVIEW BY HEALTH CANADA FOR TREATMENT OF ASTHMA WITH TYPE 2 INFLAMMATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI